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I schemia-reperfusion injury is a major contributor toearly graft failure after lung transplantation.1 The
clinical consequences of ischemia-reperfusion injury
include prolonged requirement for assisted ventilation,
need for high inspired oxygen fractions, and pulmonary
edema.2 An understanding of the pathophysiology of
ischemia-reperfusion injury is evolving, and the follow-
ing mechanisms play a role: cytokine production, neu-
trophil activation, free radical generation, lipid peroxi-
dation, and decreased number of endogenous free
radical scavengers.3,4 The therapeutic or preventive
approach to ischemia-reperfusion injury has been
designed to directly counter these pathologic processes
(eg, anti-tumor necrosis factor α antibodies5) or to aug-
ment defense systems with the addition of novel agents
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(eg, calcium channel blockers6) or endogenously pro-
duced substances (eg, superoxide dismutase7). Many of
these treatments have resulted in prolonged lung
preservation with good post-transplantation graft func-
tion in experimental models, but the elimination of
ischemia-reperfusion injury in clinical lung transplan-
tation remains a challenge.
Our approach to ameliorating ischemia-reperfusion
injury uses captopril, an angiotensin-converting
enzyme (ACE) inhibitor. Others have examined the
effectiveness of captopril in lessening ischemia-reper-
fusion injury in heart and liver models. For example,
Gurevitch and coworkers8 added captopril to the car-
dioplegic solution and administered it at reperfusion in
an isolated rat heart model. After ischemia and reperfu-
sion, the hearts that had received captopril had
improved hemodynamic measures, increased coronary
artery flow, and increased oxygen consumption. In a
study of ischemia-reperfusion injury after liver trans-
plantation, the investigators infused an ACE inhibitor,
enalapril, before reperfusion and measured the sinu-
soidal perfusion rate, leukocyte adherence, and liver
function (bile output, hepatic enzymes, and coagulation
factors). Enalapril significantly reduced leukocyte
adherence and improved all of the other parameters.9
The mechanism by which captopril exerts its protec-
tive effect is controversial and likely complex. Many
have held captopril as an example of a free radical scav-
enger10 and an inhibitor of neutrophil activity,11 where-
as others have provided evidence to the contrary.12 In
this study we hypothesized that the addition of capto-
pril to the lung flush preservation solution would (1)
ameliorate ischemia-reperfusion injury, as assessed by
blood oxygenation, peak airway pressure, and pul-
monary edema, and (2) exert its protective effect
through the reduction of neutrophil sequestration and
lipid peroxidation.
Methods
Rat left single-lung transplantation model. Inbred male
Lewis rats (250-300 g, 10-12 weeks old; Charles River
Laboratories, Inc, Quebec, Canada) were used in all groups.
The Institutional Animal Care and Use Committee of the
Toronto General Hospital reviewed and approved the protocol
for this study. All animals received humane care in accor-
dance with the “Guide for the Care and Use of Laboratory
Animals” (National Institutes of Health publication 85-23,
revised 1985).
Organ retrieval procedure. Donor rats were anesthetized by
intraperitoneal injection of 1 mL of sodium pentobarbital
(Somnotol; MTC Pharmaceuticals, Cambridge, Ontario,
Canada) and intubated through a tracheostomy with a 14-
gauge intravenous catheter. Animals were connected to a vol-
ume-controlled ventilator (Harvard Rodent Ventilator, model
683; Harvard Apparatus Co, Inc, South Natick, Mass) and
ventilated with an inspired oxygen fraction of 1 at 75
breaths/min, a tidal volume of 10 mL/kg, and a positive end-
expiratory pressure of 2 cm H2O. A median laparosternotomy
was then performed, and 300 USP of heparin (Hepalean;
Organon Teknika, Toronto, Ontario, Canada) was injected
into the inferior vena cava. For the retrieval of the heart-lung
block, the inferior vena cava was incised, the left atrial
appendage was truncated, and a 14-gauge cannula was placed
through a right ventricular outflow tractotomy into the main
pulmonary artery. The lungs were flushed through this can-
nula with 20 mL of either low-potassium dextran-glucose
solution (LPDG; n = 5; Perfadex; Biophausia, Uppsala,
Sweden) or LPDG plus captopril (n = 5) at 4°C.
Tromethamine was added to both solutions to adjust the pH
to 7.5. The flush solution in all groups contained 500 µg/L of
alprostadil (prostaglandin E1; Prostin VR; Upjohn, Don
Mills, Ontario, Canada). The study was conducted in a ran-
domized blinded fashion. Immediately after the lungs were
flushed, the endotracheal tube was clamped to keep the lungs
inflated for the duration of storage, and the heart-lung block
was excised. Care was taken to maintain hypothermic condi-
tions, during which semirigid cuffs prepared from a 14-gauge
cannula were placed into the pulmonary artery, pulmonary
vein, and main bronchus. In each case the vessel or bronchus
was drawn through the center of the cuff, everted circumfer-
entially around it, and secured with a 7-0 polypropylene lig-
ature. Each lung was then placed into 40 mL of LPDG or
LPDG plus captopril solution for 18 hours at 4°C.
Captopril preservation and flush solution. Before the start
of the study, captopril (500 µmol/L; Sigma Chemical Co, St
Louis, Mo) was dissolved in 500 mL of LPDG solution at
room temperature, reintroduced into the bag through a 0.22-
µm filter (Millex-GS; Millipore Corporation, Bedford,
Mass), and stored at 4°C. The resultant solution was colorless
and indistinguishable from standard LPDG. In addition, there
was no significant difference in the osmolarity between
groups.
Transplantation procedure. Age-, sex-, strain-, and weight-
matched recipient animals were anesthetized and intubated as
described for donor animals. The animals’ lungs were venti-
lated in a similar fashion. For measurement of the peak air-
way pressure after graft reperfusion, a 3-way tap was insert-
ed between the endotracheal tube and the ventilator circuit
and connected to a pressure transducer. The condition of the
recipient was monitored by blood pressure measurement
through a 22-gauge cannula placed in the right carotid artery.
A left-sided thoracotomy was performed through the fifth
intercostal space. The left lung was mobilized by dividing the
pulmonary ligament. The hilum of the left lung was dissect-
ed, and the pulmonary artery, pulmonary vein, and the left
main bronchus were identified and isolated. All 3 structures
were clamped with microsurgical aneurysm clamps. All 3
structures were incised on their anterior aspect, and the 3
cuffs of the donor lung were placed into the equivalent recip-
ient structures and fixed with a 7-0 polypropylene suture.
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After a standardized total warm ischemic time of 20 minutes,
the transplanted lung was reinflated, and blood was reintro-
duced by releasing the pulmonary vein followed by the arte-
rial clamps. Immediately after graft reperfusion, the recipi-
ent’s native left lung was excised, and the transplanted lung
was placed in the anatomic position in the chest. A 19-gauge
drainage catheter (Butterfly-19; Abbott Laboratories Ltd,
Saint Laurent, Quebec, Canada) was placed into the left
pleural space to avoid accumulation of fluid in the chest. The
thoracotomy was closed loosely, and the recipient animal was
ventilated with an inspired oxygen fraction of 1.0, a rate of 75
breaths/min, a tidal volume of 10 mL/kg, and a positive end-
expiratory pressure of 2 cm H2O for 2 hours.
Nontransplanted flushed lungs. Left lungs that were
flushed with LPDG and harvested from 5 Lewis rats were
processed as nontransplanted flushed lungs for biochemical
comparisons.
Measurement of lung graft function. Recipient systolic
arterial blood pressure, peak airway pressure, and oxygena-
tion of graft venous blood were assessed at the end of the 2-
hour reperfusion period. Blood was sampled under direct
vision by means of a heparinized needle inserted into the pul-
monary vein distal to the anastomotic cuff directed toward the
donor lung.
Tissue samples. The lung was divided into thirds. The
superior third was used for wet/dry weight ratio, the mid-
dle third was processed for myeloperoxidase (MPO) and
F2-isoprostane analyses (snap frozen in liquid nitrogen and
stored at –70°C), and the inferior third was used for histo-
logic examination (fixed in 10% formalin and embedded in
paraffin).
Wet/dry weight ratio. The superior third of the transplant-
ed and reperfused lung was weighed and then placed in an
oven at 100°C for 72 hours. After this drying procedure, the
portion was reweighed, and the ratio of the weight before and
after drying was calculated. This measure reflects lung water
or pulmonary edema.
MPO activity assay. Lung tissue was assayed for MPO
activity, an index of polymorphonuclear neutrophil seques-
tration, according to the method of Suzuki and coworkers.13
MPO activity was assessed at 37°C by monitoring the change
in absorbance at 655 nm over a 3-minute period in a Cobas
FARA II centrifugal analyzer (Roche Diagnostic Systems,
Montclair, NJ). The reaction mixture contained 16 mmol/L
3,3´,5,5´-tetramethylbenzidine dissolved in N,N-dimethlyfor-
mamide in 0.22 mol/L phosphate buffer that contained NaCl,
0.11 mol/L, at pH 5.4. The reaction was initiated by the addi-
tion of hydrogen peroxide, 3 mmol/L. One unit of activity
was defined as a 1-unit change in absorbance per minute at
37°C. Protein content of samples was determined by means
of the bicinchoninic acid protein assay system (Pierce,
Rockford, Ill). MPO activity is expressed as units per mil-
ligram of protein.
F2-isoprostane tissue and serum levels. F2-isoprostanes
have been shown to be sensitive and accurate markers of tis-
sue lipid peroxidation.14 F2-isoprostane levels were deter-
mined by means of an eicosanoid immunoassay with an
acetylcholinesterase kit (Cayman Chemical, Ann Arbor,
Mich). Samples of tissue (0.3 g) and plasma (0.5 mL) were
spiked with 5000 disintegrations per minute of tritium-
labeled prostaglandin F2α. Tissue samples were blade homog-
enized in 1.0 mL of Hanks buffered salt solution without
Ca++-Mg++ phenol red at high speed on ice. Proteins (0.5-mL
sample) were precipitated with 1 mL of 100% ethanol,
allowed to stand at 4°C for 5 minutes, and removed with cen-
trifugation (1500g for 10 minutes). The supernatant contain-
ing F2-isoprostanes was then decanted, an equal volume of
15% wt/vol KOH was added, and samples were diluted to 5
mL with double-distilled water; the pH was lowered below 4
with hydrochloric acid. Samples were then passed through
preconditioned SPE-C18 reverse-phase cartridges, followed
by 5 mL of pure water and then 5 mL of high-performance
liquid chromatography–grade hexane. F2-isoprostanes were
eluted with 5 mL of ethyl acetate containing 1% methanol.
The ethyl acetate was then evaporated with nitrogen. One
milliliter of eicosanoid immunoassay resuspension buffer
was added, and samples were placed in a vortex for 30 sec-
onds and sonicated on ice 3 times for 5 seconds. Samples
were then separated for scintillation counting (250 µL) and
eicosanoid immunoassay (100 µL) analysis.
The recovery factor was determined by dividing 4× disinte-
grations per minute of sample by the amount of tritium-
labeled prostaglandin F2α added. F2-isoprostane levels in the
extracted sample were determined by dividing the eicosanoid
immunoassay (in picograms per milliliter) by the recovery
factor. Total F2-isoprostane levels were determined by divid-
ing the extracted F2-isoprostane levels by the volume (500 µL)
of the sample used for purification. Protein content of samples
was determined by means of the bicinchoninic acid protein
assay system (Pierce, Rockford, Ill), and tissue and serum lev-
els of F2-isoprotanes are expressed as picograms per mil-
ligram of protein and picograms per milliliter of plasma.
Histologic analysis. The inferior third of the lungs was
used for histologic examination 2 hours after reperfusion.
Specimens were fixed in 10% formalin, dehydrated, embed-
ded in paraffin, cut into 5-µm sections, and mounted. After
the sections were deparaffinized, they were stained with
hematoxylin and eosin. A pathologist blinded to the study
analyzed the slides for hemorrhage, ischemic changes,
inflammation, and edema.
Statistical analysis. Where the assumptions of homogene-
ity and normality were met, the t test was used. Where these
assumptions were not met, the Mann-Whitney U test was
used. The SigmaStat version 1.0 (SPSS, Inc, Chicago, Ill)
software package was used for all statistical analyses.
Results
Physiologic function of the transplanted lung. All
rats survived the transplant and 2-hour reperfusion
period. Fig 1 demonstrates the significant differences
in PO2, peak airway pressure, and wet/dry weight ratios
between the captopril treatment group and the control
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group. All measurements were taken 2 hours after
reperfusion. The PO2 was significantly improved in the
captopril group (312 ± 63.3 vs 202 ± 21.1 mm Hg; P =
.006). The peak airway pressure in the captopril treat-
ment group was 11.4 ± 1.1 cm H2O, whereas that mea-
sured in the control group was 15.6 ± 1.5 cm H2O (P =
.001). Captopril treatment also resulted in a significant-
ly lower wet/dry weight ratio (4.9 ± 0.4 vs 15.8 ± 10.9;
P = .008). No significant systolic blood pressure differ-
ences were noted at 2 hours after graft reperfusion
between the groups (P = .12).
Histologic analysis. Histologic sections from the
control group showed signs of severe hemorrhagic con-
gestion and interstitial edema, whereas sections from
the captopril treatment group showed moderate con-
gestion and less edema.
MPO activity. MPO activity in nontransplanted lungs
was 0.4 ± 0.2 U/mg lung protein (Fig 2). After reperfu-
sion, MPO activity in the captopril-treated group was not
significantly different from that measured in the control
group (2.5 ± 1.5 vs 1.3 ± 1.2 U/mg lung protein).
Tissue and plasma F2-isoprostanes. The nontrans-
planted lungs had a mean F2-isoprostane level of 298.4
± 58.6 pg/mg lung protein. There was no significant
difference in lung tissue F2-isoprostane level between
the captopril and the control groups (325.0 ± 96.9 vs
200.8 ± 58.6 pg/mg lung protein; Fig 3, A).
The nontransplanted rats had a mean serum F2-iso-
prostane level of 1.8 ± 1.4 pg/mL plasma. There was no
significant difference in serum level of F2-isoprostane
between the captopril-treated group (5.0 ± 1.1 pg/mL
plasma) and the control group (3.7 ± 2.5 pg/mL plas-
ma; Fig 3, B).
Discussion
We used a rat single-lung transplantation model of
ischemia-reperfusion injury to evaluate the protective
effects of captopril. We found that the addition of cap-
topril to the pulmonary preservation and flush solution
during cold ischemia resulted in significantly improved
oxygenation, peak airway pressure, and wet/dry weight
ratios measured after 18 hours of cold storage and 2
hours of reperfusion. The mechanism by which capto-
pril exerted these protective physiologic effects
remains elusive. We had hypothesized that captopril
would likely act as a free radical scavenger and
inhibitor of neutrophil activation; however, our mea-
sures of F2-isoprostane tissue and plasma levels and
MPO activity did not detect a significant ability of cap-
topril to act in this way in transplanted lungs.
This model has proven useful for the study of inter-
ventions to protect against ischemia-reperfusion injury
after lung transplantation.15 By using isogeneic rats, we
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Fig 1. Physiologic assessment of transplanted lungs. Mean ±
SD of PO2 values (A; P = .001), airway pressure values
(PAwP, B; P = .006), and wet/dry lung weight ratios (W/D, C;
P = .008) 2 hours after reperfusion (n = 5).
Fig 2. Mean ± SD of tissue MPO activity 2 hours after reper-
fusion (n = 5). There was no significant difference between
groups (P > .05).
can eliminate rejection as a confounding factor in the
assessment. We preserved the lungs for an extended
period of 18 hours to ensure that we had sufficiently
severely injured lungs. We chose to examine the sever-
ity of the ischemia-reperfusion injury 2 hours after the
start of reperfusion because this corresponds to a time
point in the clinical setting when we frequently see evi-
dence of this injurious process.
Captopril was selected because it has been shown in
other models of ischemia-reperfusion injury to improve
functional and biochemical measures.16 We added cap-
topril to both the flush and preservation solution so it
could protect the lung during the cold ischemic period.
This is important in that Salahudeen and coworkers17
have shown that cold storage induces F2-isoprostane
formation in an experimental kidney model where the
organs were stored in University of Wisconsin solution.
They were also able to effectively suppress the F2-iso-
prostane level in organs stored for 48 hours, with a
lazaroid compound that was added to the storage solu-
tion. We chose LPDG as our preservation solution,
because it is our current clinical and experimental stan-
dard of lung preservation for transplantation. We have
previously demonstrated LPDG solution to be superior
to Euro-Collins solution in a model of 12-hour pul-
monary preservation.18
Captopril has been shown to have a wide range of
activities, and it is likely that its ability to improve graft
function after ischemia-reperfusion injury is due to one
of these other mechanisms. ACE inhibition prevents
bradykinin degradation. Matoba and coworkers19
examined the effects of ACE inhibition on hypoxia and
reoxygenation injury in cardiac myocytes. Bradykinin
and cilazaprilat (an ACE inhibitor) inhibited creatine
kinase release, whereas an angiotensin receptor type 1
(AT1) inhibitor and angiotensin II did not. The ability
of cilazaprilat to reduce this injury was eliminated
when a bradykinin B2 receptor antagonist was added to
the model. Therefore, cilazaprilat was likely protective
through its ability to inhibit kininase II (bradykinin
degradation) activity.
Others have hypothesized that captopril is protective
in ischemia-reperfusion injury models because of its
ability to increase blood flow by eliminating the vaso-
constricting effect of angiotensin II.8 We noted no sys-
temic hemodynamic differences (diastolic and systolic
blood pressures) between the groups. This suggests that
captopril added to the preservation solution did not
affect systemic hemodynamics. We did not measure
pulmonary artery pressure, but it is possible that the
residue of captopril in the lung tissue exerted its effect
on local vasoregulation.
Another possible effect of ACE inhibition is a
decrease in production of angiotensin II and therefore
reduced activation of AT1 receptors. Yanagitani and
coworkers20 examined AT1 receptor-mediated peroxide
production in human macrophages. AT1 antagonism
was able to decrease peroxide production in a dose-
dependent manner.
ACE inhibition and kininase II inhibition have a
complex interaction with nitric oxide generation. Yang
and coworkers21 used a model of myocardial ischemia-
reperfusion injury in endothelial nitric oxide synthase
(eNOS) gene knockout mice to examine the effect of
ACE inhibition in an attempt to elucidate the protective
mechanism. In eNOS +/+ mice ACE inhibition was
able to reduce myocardial infarct size, whereas in
eNOS –/– mice this effect was abolished. Others have
demonstrated that ACE inhibition can decrease post-
ischemic leukocyte adhesion to endothelium.11 We
were unable to detect a difference in level of neutrophil
sequestration in our 2 study groups.
The angiotensin system has recently been noted to
have immunomodulatory interactions. Constantinescu
and coworkers22 found that captopril and lisinopril are
able to suppress the mononuclear cell production of
interleukin 12, a proinflammatory TH1 cytokine. In
another study, ACE inhibitors were able to suppress
tumor necrosis factor α production in vitro and in
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Fig 3. Mean ± SD of tissue (A) and plasma (B) F2-iso-
prostane levels 2 hours after reperfusion. There were no sig-
nificant differences between groups (P > .05).
vivo.23 The mechanism by which ACE is involved with
cytokines is not clear. It is possible that captopril was
protective in our model through interactions with the
inflammatory or immune systems. We hypothesized
that captopril would limit or prevent ischemia-reperfu-
sion injury by scavenging free radicals and inhibiting
neutrophil sequestration. To measure the effects of the
drug, we used the MPO activity and F2-isoprostane
assays. MPO activity is a measure of neutrophil seques-
tration. This oxygen-dependent enzyme is present in
azurophilic granules in neutrophils, and it is responsi-
ble for eliminating bacteria, fungi, and foreign cells.24
F2-isoprostanes are the end products of lipid peroxida-
tion reactions. These substances are produced by the
action of noncyclooxygenase-oxidative modifications
of arachidonic acid that occur after free radical attack
of phospholipids.25 They circulate in the plasma and
are excreted in the urine after phospholipase-dependent
release from activated cells. Only the MPO assay has
been previously studied in conjunction with ACE
inhibitors. Hoshida and coworkers26 used a rabbit
model of myocardial infarction caused by coronary
occlusion and reperfusion. They administered
quinapril, an ACE inhibitor, over a prolonged period to
see whether this would ameliorate the injury. They
measured a decrease in MPO activity in the treatment
group compared with the control group and hypothe-
sized that the ACE inhibitor limited the interaction
between leukocytes and the endothelium and therefore
lessened the injury. Others have measured the effect of
ACE inhibitor administration on lipid peroxidation by
thiobarbituric acid-reactive substance production assay
and have noted a significant decrease. The F2-iso-
prostane assay has not previously been used as a mea-
sure of free radical lipid peroxidation after ACE inhibi-
tion. It is also possible that captopril scavenged free
radicals but not those that cause lipid peroxidation.
Becker and coworkers27 addressed the relationship
between F2-isoprostane levels and oxygen-derived free
radical generation by noting that it is indeed possible
for free radicals to damage vascular barriers without
altering F2-isoprostane generation.
ACE inhibitors can be divided into 2 groups: non-
sulfhydryl and sulfhydryl. The importance of this dis-
tinction in the discussion of ischemia-reperfusion
injury is that sulfhydryl groups have been shown to
scavenge free radicals more effectively than agents
without sulfhydryl groups.28 However, this area is con-
troversial with evidence both supporting and refuting
the functional importance of the sulfhydryl group. One
study examined the protective effects of 2 substances
with sulfhydryl groups in a mouse model of viral
myocarditis. Suzuki and coworkers29 found that both
captopril and a sulfhydryl-containing amino acid deriv-
ative without ACE-inhibiting properties significantly
improved survival and myocardial injury but paradoxi-
cally reduced the expression of superoxide dismutase
messenger RNA. Another study compared the ability of
sulfhydryl- and nonsulfhydryl-containing ACE in-
hibitors to inhibit hydroxyl radical production by using
electron spin resonance and 5,5-dimethyl-L-pyrroline-
N-oxide as the spin trap. They found that both groups
of ACE inhibitors were capable of scavenging hydrox-
yl radicals and therefore concluded that this scavenger
ability is likely not related to the presence of the
sulfhydryl group.30 Chopra and coworkers31 examined
the ability of ACE inhibitors to scavenge free radicals
and prevent lipid peroxidation by using a free radical
generation and a microsomal thiobarbituric acid–reac-
tive substance production assay. They showed that the
sulfhydryl presence on ACE inhibitors resulted in
effective free radical scavenging but that either type of
ACE inhibitor was effective in inhibiting lipid peroxi-
dation.
It is possible that some additional beneficial effects
may have been seen if captopril had been administered
to the recipient to ensure systemic levels of the drug at
the time of graft reperfusion. However, we did not
infuse captopril intravenously for a number of reasons.
First, the nature of the lung transplantation procedure is
such that a significant drop in systemic blood pressure
with the addition of the captopril intravenously would
not be well tolerated by the animals. Direct infusion
into the pulmonary artery in this model would also be
technically difficult and would put the procedure at
risk. However, given the damaging effect of reperfu-
sion, the presence of the protective substance at this
point would likely be beneficial. In addition, we do not
know whether the effect of captopril occurs during
ischemia or whether captopril diffuses into the
parenchyma and acts at the time of reperfusion. To
fully understand when and where captopril administra-
tion is best suited, we need to understand the mecha-
nism of its action in this setting.
In summary, we have shown that captopril in the
preservation and flush solution in a rat single-lung
transplant model decreased the severity of ischemia-
reperfusion injury, as demonstrated by significantly
improved oxygenation, peak airway pressure, and post-
transplantation pulmonary edema. We were unable to
ascertain which mechanism was responsible for the
beneficial effects seen, but we were able to provide evi-
dence against the hypothesis that captopril is a free rad-
ical scavenger in this setting. Our attention should turn
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toward the other possible mechanisms of ACE
inhibitors. This might ultimately provide further insight
into the link between acute lung injury and chronic
graft dysfunction. Our ultimate goal is to be able to
apply this simple modification of lung preservation
solutions to the clinical setting to improve lung func-
tion after transplantation.
We thank Dr J. Mates for his expert technical assistance in
performing the animal procedures; S. A. Nicholson, BSc, and
Dr T. Lindsay for assistance in performing the MPO and
F2-isoprostane assays; and Dr Peter Lewycky, who reviewed
statistical analysis of this study as a biostatistician.
R E F E R E N C E S
1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM,
Novick RJ. The Registry of the International Society for Heart
and Lung Transplantation: sixteenth official report—1999. J
Heart Lung Transplant 1999;18:611-26.
2. Haydock DA, Trulock EP, Kaiser LR, Ettinger NA, Triantifillou
AN, Ochoa LL, et al. Lung transplantation: analysis of thirty-six
consecutive procedures performed over a twelvemonth period.
The Washington University Lung Transplant Group. J Thorac
Cardiovasc Surg 1992;103:329-40.
3. Ambrosio G, Tritto I. Reperfusion injury: experimental evidence
and clinical implications. Am Heart J 1999;138:69-75.
4. Grace PA. Ischaemia-reperfusion injury. Br J Surg 1994;81:637-
47.
5. Khimenko PL, Bagby GJ, Fuseler J, Taylor AE. Tumor necrosis
factor-alpha in ischemia and reperfusion injury in rat lungs. J
Appl Physiol 1998;85:2005-11.
6. Sasaki S, Yasuda K, McCully JD, LoCicero J 3rd. Calcium chan-
nel blocker enhances lung preservation. J Heart Lung Transplant
1999;18:127-32.
7. Cremer J, Jurmann M, Dammenhayn L, Wahlers T, Haverich A,
Borst HG. Oxygen free radical scavengers to prevent pulmonary
reperfusion injury after heart-lung transplantation. J Heart
Transplant 1989;8:330-6.
8. Gurevitch J, Pevni D, Frolkis I, Matsa M, Paz Y, Mohr R, et al.
Captopril in cardioplegia and reperfusion: protective effects on
the ischemic heart. Ann Thorac Surg 1997;63:627-33.
9. Anthuber M, Farkas S, Rihl M, Menger MD, Schildberg FW,
Jauch KW, et al. Angiotensin-converting enzyme inhibition by
enalapril: a novel approach to reduce ischemia/reperfusion dam-
age after experimental liver transplantation. Hepatology
1997;25:648-51.
10. Engelman RM, Rousou JA, Iyengar J, Das DK. Captopril, an
ACE inhibitor, for optimizing reperfusion after acute myocardial
infarction. Ann Thorac Surg 1991;52:918-26.
11. Kupatt C, Habazettl H, Zahler S, Weber C, Becker BF, Messmer
K, et al. ACE-inhibition prevents postischemic coronary leuko-
cyte adhesion and leukocyte-dependent reperfusion injury.
Cardiovasc Res 1997;36:386-95.
12. Johnson P, Wei Y, Huentelman MJ, Peters CM, Boldyrev AA.
Hydralazine, but not captopril, decreases free radical production
and apoptosis in neurons and thymocytes. Free Radic Res
1998;28:393-402.
13. Suzuki K, Ota H, Sasagawa S, Sakatani T, Fujikura T. Assay
method for myeloperoxidase in human polymorphonuclear
leukocytes. Anal Biochem 1983;132:345-52.
14. Morrow JD, Harris TM, Roberts L. Noncyclooxygenase oxida-
tive formation of a series of novel prostaglandins: analytical ram-
ifications for measurement of eicosanoids. Anal Biochem
1990;184:1-10.
15. Hiratsuka M, Yano M, Mora BN, Nagahiro I, Cooper JD,
Patterson GA. Heat shock pretreatment protects pulmonary iso-
grafts from subsequent ischemia-reperfusion injury. J Heart Lung
Transplant 1998;17:1238-46.
16. Vargas AV, Robinson AV, Schulak JA. Captopril amelioration of
renal reperfusion injury. J Surg Res 1994;57:28-32.
17. Salahudeen A, Nawaz M, Poovala V, Kanji V, Wang C, Morrow
J, et al. Cold storage induces time-dependent F2-isoprostane for-
mation in renal tubular cells and rat kidneys. Kidney Int
1999;55:1759-62.
18. Keshavjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson
GA, Cooper JD. A method for safe twelve-hour pulmonary
preservation. J Thorac Cardiovasc Surg 1989;98:529-34.
19. Matoba S, Tatsumi T, Keira N, Kawahara A, Akashi K, Kobara
M, et al. Cardioprotective effect of angiotensin-converting
enzyme inhibition against hypoxia/reoxygenation injury in cul-
tured rat cardiac myocytes. Circulation 1999;99:817-22.
20. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S,
Ohishi M, et al. Angiotensin II type 1 receptor-mediated perox-
ide production in human macrophages. Hypertension
1999;33:335-9.
21. Yang XP, Liu YH, Shesely EG, Bulagannawar M, Liu F,
Carretero OA. Endothelial nitric oxide gene knockout mice: car-
diac phenotypes and the effect of angiotensin-converting enzyme
inhibitor on myocardial ischemia/reperfusion injury. Hyper-
tension 1999;34:24-30.
22. Constantinescu CS, Goodman DB, Ventura ES. Captopril and
lisinopril suppress production of interleukin-12 by human
peripheral blood mononuclear cells. Immunol Lett 1998;62:25-
31.
23. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S,
et al. Angiotensin converting enzyme inhibitors suppress produc-
tion of tumor necrosis factor-alpha in vitro and in vivo.
Immunopharmacology 1997;36:49-55.
24. Lanza F. Clinical manifestation of myeloperoxidase deficiency. J
Mol Med 1998;76:676-81.
25. Patrono C, Fitzgerald GA. Isoprostanes: potential markers of oxi-
dant stress in atherothrombotic disease. Arterioscler Thromb Vasc
Biol 1997;17:2309-15.
26. Hoshida S, Yamashita N, Kawahara K, Kuzuya T, Hori M.
Amelioration by quinapril of myocardial infarction induced by
coronary occlusion/reperfusion in a rabbit model of atherosclero-
sis: possible mechanisms. Circulation 1999;99:434-40. 
27. Becker PM, Sanders SP, Price P, Christman BW. F2-isoprostane
generation in isolated ferret lungs after oxidant injury or ventilat-
ed ischemia. Free Radic Biol Med 1998;25:703-11.
28. Fernandes AC, Filipe PM, Freitas JP, Manso CF. Different effects
of thiol and nonthiol ACE inhibitors on copper- induced lipid and
protein oxidative modification. Free Radic Biol Med
1996;20:507-14.
29. Suzuki H, Matsumori A, Matoba Y, Kyu BS, Tanaka A, Fujita J,
et al. Enhanced expression of superoxide dismutase messenger
RNA in viral myocarditis: an SH-dependent reduction of its
expression and myocardial injury. J Clin Invest 1993;91:2727-33.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 3
Fischer et al 579
30. Suzuki S, Sato H, Shimada H, Takashima N, Arakawa M.
Comparative free radical scavenging action of angiotensin-con-
verting enzyme inhibitors with and without the sulfhydryl radical.
Pharmacology 1993;47:61-5.
31. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE,
McMurray J. Antioxidant effects of angiotensin-converting
enzyme (ACE) inhibitors: free radical and oxidant scavenging are
sulfhydryl dependent, but lipid peroxidation is inhibited by both
sulfhydryl- and nonsulfhydryl- containing ACE inhibitors. J
Cardiovasc Pharmacol 1992;19:330-40.
580 Fischer et al The Journal of Thoracic and
Cardiovascular Surgery
September 2000
Don’t miss a single issue of the journal!  To ensure prompt service when you change your address, please pho-
tocopy and complete the form below. 
Please send your change of address notification at least six weeks before your move to ensure continued service.
We regret we cannot guarantee replacement of issues missed due to late notification.
JOURNAL TITLE:
Fill in the title of the journal here.
OLD ADDRESS:
Affix the address label from a recent issue of the journal here.
NEW ADDRESS:
Clearly print your new address here.
Name
Address
City/State/ZIP
COPY AND MAIL THIS FORM TO: OR FAX TO: OR PHONE:
Mosby 407-363-9661 800-654-2452
Subscription Customer Service Outside the U.S., call
6277 Sea Harbor Dr 407-345-4000
Orlando, FL  32887
Send us your new address at least six weeks aheadO N THE MOVE?
